Studien
Eine kleine Übersicht zur Auswahl
ad Myelodysplastisches Syndrom (MDS)
MECHANISMS OF DISEASE - Myelodysplastic Syndromes
Ayalew Tefferi, M.D., and James W. Vardiman, M.D.
N Engl J Med 2009; 361:1872-85, November 2009
Current therapeutic approaches for patients with myelodysplastic syndromes
Peter L. Greenberg
British Journal of Haematology; Volume 150, Issue 2, pages 131–143, July 2010
doi:10.1111/j.1365-2141.2010.08226.x
ad Azacitidin:
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Prof Pierre Fenaux MD, Prof Ghulam J Mufti MD, Prof Eva Hellstrom-Lindberg MD, Valeria Santini MD, Carlo Finelli MD, Aristoteles Giagounidis MD, Robert Schoch MD, Norbert Gattermann MD, Guillermo Sanz MD, Prof Alan List MD, Prof Steven D Gore MD, John F Seymour MBBS, Prof John M Bennett MD, Prof John Byrd MD, Jay Backstrom MD, Linda Zimmerman BSN, David McKenzie MS, CL Beach PharmD, Lewis R Silverman MD, for the International Vidaza High-Risk MDS Survival Study Group
The Lancet Oncology; Volume 10, Issue 3, Pages 223 - 232, March 2009
doi:10.1016/S1470-2045(09)70003-8
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
Katharina Götze, Uwe Platzbecker, Aristoteles Giagounidis, Detlef Haase, Michael Lübbert, Carlo Aul, Arnold Ganser, Ulrich Germing and Wolf-Karsten Hofmann
Annals of Hematology; Volume 89, Number 9, 841-850
DOI: 10.1007/s00277-010-1015-0
ad Lenalidomid:
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion